ClinicalTrials.gg
Not yet recruitingNCT07219667Updated May 19, 2026

South Asians With Type 2 Diabetes at Risk for Depression

An interventional study of CHW-led T2D Intervention in Type 2 Diabetes, sponsored by NYU Langone Health. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Health services research

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Diabetes Mellitus, Type 2 by NYU Langone Health — 6 open to participants now, 6 under way, none of them phase 3. Diabetes Mellitus, Type 2 · NYU Langone Health.

Planned enrollment
12th of 23
100 · median 100
Started
2027
with 1 other
No phase
20 of 25
6 open now
Registered
24th of 25
by date

Among the 25 studies in Diabetes Mellitus, Type 2 by NYU Langone Health, this one is the 12th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2027, is one of 20 with no phase, and was the 24th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 25 studies in Diabetes Mellitus, Type 2 by NYU Langone Health are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Diabetes Mellitus, Type 2 by NYU Langone Health, or all of them as a file.
02

Study summary

This study will adapt a community health worker (CHW)-led Type 2 diabetes (T2D) intervention to include mental health and digital components using a trauma informed care approach, and test the feasibility and acceptability of this intervention to support South Asians with T2D at risk for depression.

Read the detailed description

Specific Aim 1: Examine factors associated with distress, poor mental health, and comorbid T2D and depression among South Asians to inform pilot study structure and content.

Specific Aim 2: Adapt CHW-led T2D intervention to include mental health and digital components using a trauma-informed care approach and the ecological validity model.

Specific Aim 3: Evaluate the feasibility and acceptability of a pilot CHW-led intervention to support participants with T2D who are at risk for depression.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Aim 1 (Qualitative Component):

  • South Asian ethnicity based on self-report information
  • 18 years of age or older
  • Residing in NYC
  • Willingness and capacity to provide consent

Aim 3: Pilot Intervention:

  • South Asian ethnicity based on patient demographic information
  • 18 to 75 years of age
  • Appointment for routine non-emergent primary care in the past 12 months
  • Diagnosis of Type 2 diabetes
  • Patient Health Questionnaire-9 (PHQ-9) score of ≥5 (mild to severe depression)
  • Residing in NYC
  • Willingness and capacity to provide consent

Exclusion criteria

Exclusion Criteria:

Aim 1 (Qualitative Component):

  • Diagnosed cognitive deficits or limited decision-making capacity

Aim 3: Pilot Intervention:

  • Pregnant at the time of screening
  • Type 1 diabetes or diabetes secondary to other conditions (e.g., -induced, pancreatic insufficiency)
  • or life-threatening illness with a of \<5 years
  • Inability to perform unsupervised physical activity
  • Diagnosed cognitive deficits or limited decision-making capacity
  • Currently taking anti-depressant medication or receiving counseling services.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Adult South Asian patients in the New York City (NYC) region

    In Aim 3, CHWs will provide culturally and linguistically tailored health education to South Asian participants on the management of T2D and depressive symptoms.

    Behavioral: CHW-led T2D Intervention

Interventions

  • BehavioralCHW-led T2D Intervention

    CHW-led T2D intervention that includes mental health and digital health components.

06

What researchers measure

Primary outcomes

  1. Change in HbA1c Levels

    Change in glycated hemoglobin (HbA1c).

    Time frame: Baseline, Month 3

  2. Change in Diabetes Distress Scale (DDS) Score

    The Diabetes Distress Scale (DDS) is a 17-item psychological questionnaire designed to assess the emotional and psychological distress experienced by individuals with diabetes. Each item is rated on a scale of 0 to 6. The total score is calculated by summing up the scores of all 17 items and ranges from 0-102; higher scores indicate greater distress.

    Time frame: Baseline, Month 3

  3. Change in Patient Health Questionnaire-9 (PHQ-9) Score

    The PHQ-9 is a 9-item questionnaire to assess depressive symptoms. Each item is scored from 0 (not at all) to 3 (nearly every day). The total score ranges from 0 to 27. Higher scores indicate greater severity of depression.

    Time frame: Baseline, Month 3

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — All of the individual participant data collected during the trial, after deidentification, will be shared with researchers who provide a methodologically sound proposals, provided the requesting researcher executes a data use agreement with NYU Langone Health. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's Data Sharing Strategy Board (DSSB). Study data will be deposited into the repository at the time of an associated study publication or end of performance period, whichever comes first. The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Study data will be deposited into the repository at the time of an associated study publication or end of performance period, whichever comes first.

Access criteria: Data are available for 5 years at a third party website (Link to be included).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2027; primary completion for Jun 2028, 10 months later.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 10 months is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2025
First posted
Oct 22, 2025
StartEst.
Aug 1, 2027
Primary completionEst.
Jun 1, 2028
CompletionEst.
Jun 1, 2028
Last update
May 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07219667
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Oct 22, 2025
Start date
Aug 1, 2027 (estimated)
Primary completion
Jun 1, 2028 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
May 19, 2026

Study contacts

Naheed Ahmed, PhD
Contact
Naheed.Ahmed@nyulangone.org
646-501-3751
Naheed Ahmed, PhD
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion